MX2019009153A - Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab. - Google Patents

Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.

Info

Publication number
MX2019009153A
MX2019009153A MX2019009153A MX2019009153A MX2019009153A MX 2019009153 A MX2019009153 A MX 2019009153A MX 2019009153 A MX2019009153 A MX 2019009153A MX 2019009153 A MX2019009153 A MX 2019009153A MX 2019009153 A MX2019009153 A MX 2019009153A
Authority
MX
Mexico
Prior art keywords
her2
pertuzumab
treating
cancer
positive
Prior art date
Application number
MX2019009153A
Other languages
English (en)
Inventor
Alavattam Sreedhara
C Amler Lukas
C Benyunes Mark
L Clark Emma
H De Toledo Pelizon Christina
W Kwong Glover Zephania
Mitchell Lada
Ratnayake Jayantha
A Ross Graham
Amir Walker Ru-
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47073543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019009153(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2019009153A publication Critical patent/MX2019009153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Packages (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente solicitud describe usos y artículos de fabricación que incluyen Pertuzumab, un inhibidor de la dimerización de HER2 primero en su clase. En particular, la solicitud describe métodos para prolongar la supervivencia sin evolución en una población de pacientes con cáncer de mama HER2 positivo; combinar dos anticuerpos HER2 para tratar el cáncer HER2 positivo sin aumentar la toxicidad cardíaca; tratar el cáncer de mama HER2 positivo en etapa temprana; tratar el cáncer HER2 positivo mediante la administración conjunta de una mezcla de Pertuzumab y Trastuzumab desde la misma bolsa intravenosa; tratar el cáncer gástrico metastásico HER2 positivo; tratar el cáncer de mama HER2 positivo con Pertuzumab, Trastuzumab y Vinorelbina; tratar el cáncer de mama HER2 positivo con Pertuzumab, Trastuzumab e inhibidor de aromatasa; y tratar el cáncer de ovario, peritoneal primario o de trompas de falopio con HER3 bajo. También describe un artículo de fabricación que comprende un vial que contiene Pertuzumab y un prospecto que proporciona datos de seguridad y/o eficacia; un método para producir un artículo de fabricación; y un método para asegurar el uso seguro y eficaz del Pertuzumab relacionado con este. Además, la solicitud describe una bolsa intravenosa (IV) que contiene una mezcla estable de Pertuzumab y Trastuzumab adecuada para la administración a un paciente con cáncer.
MX2019009153A 2011-10-14 2014-04-03 Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab. MX2019009153A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161547535P 2011-10-14 2011-10-14
US201161567015P 2011-12-05 2011-12-05
US201261657669P 2012-06-08 2012-06-08
US201261682037P 2012-08-10 2012-08-10
US201261694584P 2012-08-29 2012-08-29

Publications (1)

Publication Number Publication Date
MX2019009153A true MX2019009153A (es) 2019-10-14

Family

ID=47073543

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014004021A MX2014004021A (es) 2011-10-14 2012-10-11 Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.
MX2019009153A MX2019009153A (es) 2011-10-14 2014-04-03 Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014004021A MX2014004021A (es) 2011-10-14 2012-10-11 Usos y articulo de fabricacion que incluye el inhibidor de la dimerizacion de her2 pertuzumab.

Country Status (29)

Country Link
US (9) US20130095172A1 (es)
EP (5) EP2766040B1 (es)
JP (8) JP2014530235A (es)
KR (4) KR20230028585A (es)
CN (8) CN116271013A (es)
AU (4) AU2012322797B2 (es)
BR (1) BR112014007521A8 (es)
CL (1) CL2014000889A1 (es)
DK (1) DK2766040T3 (es)
EA (1) EA034390B1 (es)
ES (1) ES2736005T3 (es)
HK (1) HK1202242A1 (es)
HR (1) HRP20191247T1 (es)
HU (1) HUE044352T2 (es)
IL (4) IL301603A (es)
IN (1) IN2014CN02703A (es)
LT (1) LT2766040T (es)
MX (2) MX2014004021A (es)
MY (2) MY172326A (es)
PE (1) PE20142363A1 (es)
PH (1) PH12019500519A1 (es)
PL (1) PL2766040T3 (es)
PT (1) PT2766040T (es)
RS (1) RS58944B1 (es)
SG (3) SG11201401432XA (es)
SI (1) SI2766040T1 (es)
UA (2) UA123092C2 (es)
WO (1) WO2013055874A2 (es)
ZA (1) ZA201401259B (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
ES2647317T3 (es) 2008-11-03 2017-12-20 Syntarga B.V. Análogos de CC-1065 y sus conjugados
DK3108886T3 (da) 2010-04-21 2020-08-10 Syntarga Bv Konjugater af CC-1065-analoger og bifunktionelle linkere
US20130095172A1 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
CA3071678A1 (en) 2013-04-16 2014-10-23 Genentech,Inc. Pertuzumab variants and evaluation thereof
EP3010501B1 (en) * 2013-06-19 2021-11-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
BR112016013896A2 (pt) 2013-12-17 2017-10-10 Genentech Inc métodos de tratamento de câncer positivo para her2 usando antagonistas de ligação do eixo de pd-1 e anticorpos anti-her2
CN104726462A (zh) * 2013-12-20 2015-06-24 北京天广实生物技术股份有限公司 抗her2人源化抗体mil41、其制备方法及用途
EP3069735B1 (en) * 2014-01-10 2018-03-14 Synthon Biopharmaceuticals B.V. Duocarmycin adcs for use in the treatment of bladder cancer
EP3092010B1 (en) 2014-01-10 2018-07-11 Synthon Biopharmaceuticals B.V. Method for purifying cys-linked antibody-drug conjugates
KR20160099725A (ko) * 2014-01-10 2016-08-22 신톤 바이오파머슈티칼즈 비.브이. 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
WO2016094341A1 (en) * 2014-12-08 2016-06-16 Synta Pharmaceuticals Corp. Triple combination therapy, comprising ganetespib, a taxane and an antibody, for use in the treatment of her2 positive breast cancer
US10208130B2 (en) 2015-05-29 2019-02-19 Expression Pathology, Inc. Quantifying Her2 protein for optimal cancer therapy
CN107771076A (zh) * 2015-06-17 2018-03-06 豪夫迈·罗氏有限公司 使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
MA45324A (fr) 2016-03-15 2019-01-23 Seattle Genetics Inc Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
EP3534948A1 (en) * 2016-11-04 2019-09-11 Genentech, Inc. Treatment of her2-positive breast cancer
CN110099926A (zh) * 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 晚期her2表达性癌症的治疗
CR20190376A (es) * 2017-01-17 2019-11-20 Genentech Inc Formulaciones de anticuerpos de her2 subcutáneas
EP3589661B1 (en) * 2017-03-02 2023-11-01 Genentech, Inc. Adjuvant treatment of her2-positive breast cancer
KR102267593B1 (ko) * 2018-10-19 2021-06-21 주식회사 프로티나 Her2 및 her3의 헤테로다이머를 표적으로 하는 약물 및 이의 스크리닝 방법
CN114728101B (zh) * 2019-06-28 2023-07-14 德州大学系统董事会 重构脂质体安那霉素的方法
BR112021026506A2 (pt) 2019-06-28 2022-02-15 Univ Texas Método para fabricar anamicina liofilizada, método para produzir liofilizado de anamicina pré-lipossômico, composição de liofilizado de anamicina pré-lipossômico e método para tratar câncer
WO2021222068A1 (en) * 2020-04-29 2021-11-04 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compositions and methods for detecting gene fusions of esr1 and ccdc170 for determining increased resistance to endocrine therapy and for cancer treatment
CN111710425A (zh) * 2020-06-19 2020-09-25 复旦大学附属中山医院 一种免疫检查点抑制剂心脏毒性评估方法，系统及装置
WO2023108012A1 (en) * 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL74201A0 (en) 1984-01-30 1985-04-30 Icrf Patents Limited Polypeptides for the detection and control of mammalian cell growth
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
DE69031120T2 (de) 1989-05-19 1998-01-15 Genentech Inc Her2 extrazellulare domäne
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
JPH11510170A (ja) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
PT950067E (pt) 1996-11-27 2007-12-06 Genentech Inc Purificação por afinidade de um polipéptido numa matriz de proteína a.
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AU765003B2 (en) 1998-03-27 2003-09-04 Genentech Inc. Apo-2 ligand-anti-her-2 antibody synergism
AU760048B2 (en) 1998-05-06 2003-05-08 Genentech Inc. Protein purification by ion exchange chromatography
US6573043B1 (en) 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
EP1187632B1 (en) 1999-05-14 2008-12-03 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES
US20040013667A1 (en) 1999-06-25 2004-01-22 Genentech, Inc. Treatment with anti-ErbB2 antibodies
CN100340575C (zh) 1999-06-25 2007-10-03 杰南技术公司 人源化抗ErbB2抗体及其在制备药物中的应用
AU779209B2 (en) 1999-06-25 2005-01-13 Genentech Inc. Treating prostate cancer with anti-ErbB2 antibodies
US20030086924A1 (en) 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
TR200200472T2 (tr) 1999-08-27 2002-06-21 Genentech, Inc. Anti-Erb B2 antikorları ile tedavi için dozajlar
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
US6632979B2 (en) 2000-03-16 2003-10-14 Genentech, Inc. Rodent HER2 tumor model
CN102698265A (zh) 2000-05-19 2012-10-03 杰南技术公司 用于提高对ErbB 拮抗剂癌症治疗的有效应答可能性的基因检测试验
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
EP2325205A3 (en) 2000-12-28 2011-10-12 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
SI1501856T1 (sl) 2002-04-10 2013-04-30 Genentech, Inc. Variante protitelesa proti HER2
US20050276812A1 (en) 2004-06-01 2005-12-15 Genentech, Inc. Antibody-drug conjugates and methods
PT2263691E (pt) 2002-07-15 2012-11-12 Hoffmann La Roche Tratamento de cancro com o anticorpo anti-erbb2 monoclonal humanizado recombinante 2c4 (rhumab 2c4)
EP3388452A3 (en) 2002-09-11 2019-02-20 Genentech, Inc. Protein purification
AU2003277044A1 (en) * 2002-09-30 2004-04-23 The Trustees Of Boston University Method of treating cancer using adenosine and its analogs
AU2003295798B2 (en) 2002-11-21 2009-09-10 Genentech, Inc. Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies
SI3095793T1 (sl) 2003-07-28 2020-07-31 Genentech, Inc. Zmanjšanje izluževanja proteina A med afinitetno kromatografijo proteina A
EP1737489B1 (en) 2004-04-08 2012-01-11 David B Agus ErbB2 antagonists for tumor pain therapy
GT200500155A (es) 2004-06-16 2006-05-15 Terapia del càncer resistente al platino
US20050280299A1 (en) 2004-06-18 2005-12-22 Alfmeier Corporation Mounting adaptor for seat assembly, and seat assembly having mounting adaptor
KR20180091967A (ko) 2004-07-22 2018-08-16 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
EP1778728A2 (en) 2004-08-19 2007-05-02 Genentech, Inc. Polypeptide variants with altered effector function
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2008518902A (ja) * 2004-11-04 2008-06-05 ファイザー・プロダクツ・インク 乳癌のためのｃｔｌａ４抗体とアロマターゼ阻害剤の併用治療
WO2006063042A2 (en) 2004-12-07 2006-06-15 Genentech, Inc. Selecting patients for therapy with a her inhibitor
KR20170134771A (ko) * 2005-01-21 2017-12-06 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
SI3248600T1 (sl) * 2005-02-18 2020-09-30 Abraxis Bioscience, Llc Kombinacije in načini dajanja terapevtskih sredstev in kombinacijska terapija
KR101253576B1 (ko) 2005-02-23 2013-04-11 제넨테크, 인크. Ｈｅｒ 이량체화 억제제를 이용한 암 환자에서의 질환진행까지의 시간 또는 생존의 연장
TW200642695A (en) 2005-03-08 2006-12-16 Genentech Inc Methods for identifying tumors responsive to treatment with her dimerization inhibitors (HDIs)
US20060212956A1 (en) 2005-03-14 2006-09-21 Genentech, Inc. Animal model of ligand activated HER2 expressing tumors
JP2006316040A (ja) 2005-05-13 2006-11-24 Genentech Inc Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
MY157955A (en) 2005-07-06 2016-08-30 Hoffmann La Roche Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (es) 2005-07-22 2007-03-09 Genentech Inc Tratamiento combinado de los tumores que expresan el her
US7700299B2 (en) 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
TW200812615A (en) 2006-03-22 2008-03-16 Hoffmann La Roche Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2
US20080038271A1 (en) * 2006-06-05 2008-02-14 Amler Lukas C Extending survival of cancer patients with elevated levels of EGF or TGF-alpha
US7816300B2 (en) 2006-06-14 2010-10-19 Cataler Corporation Catalyst for purifying exhaust gas
SG174090A1 (en) 2006-08-21 2011-09-29 Hoffmann La Roche Tumor therapy with an anti-vegf antibody
WO2008031531A1 (en) * 2006-09-15 2008-03-20 F. Hoffmann-La Roche Ag Tumor therapy with a combination of anti-her2 antibodies
EP2899541A1 (en) 2007-03-02 2015-07-29 Genentech, Inc. Predicting response to a HER dimerisation inhbitor based on low HER3 expression
KR101169243B1 (ko) 2007-06-06 2012-08-02 에프. 호프만-라 로슈 아게 종양 항원에 결합하는 비-표지된 제 1 단클론 항체 및 ｎｉｒ 형광 표지로 표지된 비-교차 반응성 제 2 단클론 항체로 이루어진 조성물
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
PL2171090T3 (pl) 2007-06-08 2013-09-30 Genentech Inc Markery ekspresji genów odporności guza na leczenie hamujące HER2
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
JP2011500684A (ja) * 2007-10-19 2011-01-06 バイパー サイエンシズ，インコーポレイティド ベンゾピロン系ｐａｒｐ阻害剤を用いる癌の処置方法および組成物
DK2215117T4 (en) 2007-10-30 2018-04-09 Genentech Inc ANTISTO PURIFICATION BY CATION CHANGE CHROMATOGRAPHY
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
US20090203015A1 (en) * 2008-02-13 2009-08-13 Celera Corporation Multiplex assays for hormonal and growth factor receptors, and uses thereof
JP2011513432A (ja) 2008-03-06 2011-04-28 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ及びＨＥＲアンタゴニストの併用療法
HUE025507T2 (en) 2008-03-18 2016-02-29 Genentech Inc Combinations of anti-HER2 antibody-drug conjugate and chemotherapeutic agents and methods for their use
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
SI2752189T1 (sl) * 2008-11-22 2017-02-28 F. Hoffmann-La Roche Ag Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
SG10201507044PA (en) 2009-05-29 2015-10-29 Hoffmann La Roche Modulators for her2 signaling in her2 expressing patients with gastric cancer
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
US20110165155A1 (en) * 2009-12-04 2011-07-07 Genentech, Inc. Methods of treating metastatic breast cancer with trastuzumab-mcc-dm1
US20130095172A1 (en) 2011-10-14 2013-04-18 Genentech, Inc. Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab

Also Published As

Publication number Publication date
EA201490779A1 (ru) 2015-11-30
KR20170023195A (ko) 2017-03-02
US20210015919A1 (en) 2021-01-21
CN116236569A (zh) 2023-06-09
CN109908341B (zh) 2023-06-27
IL286921A (en) 2021-10-31
EP4241849A2 (en) 2023-09-13
IL231350A0 (en) 2014-04-30
AU2012322797A1 (en) 2014-03-20
CN109908341A (zh) 2019-06-21
MY194408A (en) 2022-11-30
KR102099991B1 (ko) 2020-04-14
JP2020090507A (ja) 2020-06-11
US20230277664A1 (en) 2023-09-07
SI2766040T1 (sl) 2019-08-30
CN114984205A (zh) 2022-09-02
US20160175438A1 (en) 2016-06-23
PL2766040T3 (pl) 2019-11-29
NZ621367A (en) 2016-04-29
JP2023109780A (ja) 2023-08-08
CL2014000889A1 (es) 2014-07-25
LT2766040T (lt) 2019-08-12
US20190117769A1 (en) 2019-04-25
CN116808199A (zh) 2023-09-29
DK2766040T3 (da) 2019-07-22
JP2023109779A (ja) 2023-08-08
PT2766040T (pt) 2019-07-11
CN104334189A (zh) 2015-02-04
EP3598981A2 (en) 2020-01-29
CN116271011A (zh) 2023-06-23
EP4234033A2 (en) 2023-08-30
UA123092C2 (uk) 2021-02-17
EP4234033A3 (en) 2023-09-20
US20130095172A1 (en) 2013-04-18
EP2766040A2 (en) 2014-08-20
KR20230028585A (ko) 2023-02-28
US20220362379A1 (en) 2022-11-17
KR20230073340A (ko) 2023-05-25
HK1202242A1 (en) 2015-09-25
ES2736005T3 (es) 2019-12-23
AU2016204962A1 (en) 2016-08-04
JP7303957B1 (ja) 2023-07-05
US20230277663A1 (en) 2023-09-07
CN116271013A (zh) 2023-06-23
ZA201401259B (en) 2019-01-30
MY172326A (en) 2019-11-21
BR112014007521A2 (pt) 2017-12-12
AU2019261666B2 (en) 2021-08-05
EP4241849A3 (en) 2023-09-20
WO2013055874A2 (en) 2013-04-18
AU2012322797B2 (en) 2016-04-21
JP2020033353A (ja) 2020-03-05
EP4234034A3 (en) 2023-09-20
KR20140075725A (ko) 2014-06-19
HUE044352T2 (hu) 2019-10-28
KR102502545B1 (ko) 2023-02-21
SG10202110077QA (en) 2021-10-28
IL309917A (en) 2024-03-01
JP2022062010A (ja) 2022-04-19
EP4234034A2 (en) 2023-08-30
AU2019261666A1 (en) 2019-11-28
IL231350B2 (en) 2023-08-01
AU2018203970A1 (en) 2018-06-21
JP7352760B2 (ja) 2023-09-28
IN2014CN02703A (es) 2015-07-03
IL301603A (en) 2023-05-01
US20200206348A1 (en) 2020-07-02
CN116271011B (zh) 2023-10-27
EA034390B1 (ru) 2020-02-03
AU2016204962B2 (en) 2018-03-08
JP6646785B1 (ja) 2020-02-14
JP2017222663A (ja) 2017-12-21
AU2018203970B2 (en) 2019-11-21
JP2014530235A (ja) 2014-11-17
CN117018187A (zh) 2023-11-10
PH12019500519A1 (en) 2021-06-14
UA116095C2 (uk) 2018-02-12
MX2014004021A (es) 2014-04-30
BR112014007521A8 (pt) 2018-04-10
HRP20191247T1 (hr) 2019-10-18
AU2012322797A8 (en) 2014-06-26
EP3598981A3 (en) 2020-06-10
IL231350B1 (en) 2023-04-01
SG10201606756PA (en) 2016-10-28
US20200376120A1 (en) 2020-12-03
WO2013055874A3 (en) 2013-06-20
JP2024009803A (ja) 2024-01-23
SG11201401432XA (en) 2014-05-29
EP2766040B1 (en) 2019-05-15
RS58944B1 (sr) 2019-08-30
PE20142363A1 (es) 2015-01-30
NZ750877A (en) 2020-09-25

Similar Documents

Publication Publication Date Title
PH12019500519A1 (en) Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab
NZ719784A (en) Specific anti-cd38 antibodies for treating human cancers
MX2015015110A (es) Anticuerpos que se unen especificamente a her2.
SG10201811128RA (en) Ezh2 inhibitors for treating lymphoma
MX356704B (es) Combinación.
HRP20230523T1 (hr) Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta
PH12016501554A1 (en) Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
NZ625758A (en) Method for treating breast cancer
EA201792286A1 (ru) Способы лечения рака
MX2017001176A (es) Terapia de combinacion.
MX2016006894A (es) Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.
PH12016500677A1 (en) Specific anti-cd38 antibodies for treating human cancers
EA201991164A1 (ru) Применение ингибитора димеризации her2 пертузумаба в качестве промышленного изделия и промышленное изделие, включающее ингибитор димеризации her2 пертузумаб
MX2017009733A (es) Uso de una mezcla de polímeros de glucosa modificados para reducir la metástasis tumoral.
NZ742470A (en) Combination therapy for cancer
MX2015016893A (es) Combinacion de ro5503781 y capecitabina para la terapia para el cancer.
UA105159C2 (uk) Спосіб лікування рецидиву варикозної хвороби нижніх кінцівок